US regulators recall 10-minute Ebola test
US regulators have issued an international recall for a 10-minute Ebola blood test made by a California-based company, saying it has not been proven to work and could put lives at risk.
Apr 23, 2015
1
2
US regulators have issued an international recall for a 10-minute Ebola blood test made by a California-based company, saying it has not been proven to work and could put lives at risk.
Apr 23, 2015
1
2
A top federal drug regulator says increased safety problems with homeopathic remedies contributed to the government's decision to revisit its oversight of the products this week.
Apr 21, 2015
0
13
(HealthDay)—The first U.S. generic version of Copaxone (glatiramer acetate injection) has been approved by the Food and Drug Administration to treat multiple sclerosis.
Apr 17, 2015
0
2
Droperidol is safe and effective for calming violent and aggressive emergency patients, and the negative effects that garnered a black box warning from the Food and Drug Administration (FDA) are actually quite rare. A new ...
Apr 17, 2015
0
4
Patients with chronic heart failure, a deadly disease that worsens as the heart pumps less blood through the body, are getting a much-needed new option.
Apr 15, 2015
0
7
The nation's largest tobacco companies are suing the Food and Drug Administration over recent guidelines that they claim overstep the agency's authority over labeling and packaging for cigarettes and other tobacco products.
Apr 14, 2015
0
2
A medical skin patch tested by Seattle-area doctors and families to treat dangerous peanut allergies in children will receive accelerated regulatory review, officials said Thursday.
Apr 14, 2015
0
14
Canadian drugmaker Tekmira Pharmaceuticals said Friday it will restart a study of an experimental Ebola treatment in the coming weeks.
Apr 10, 2015
0
13
Government advisers recommended against a proposal by Swedish Match to market its smokeless tobacco pouches as less harmful than cigarettes and other tobacco products.
Apr 10, 2015
0
3
The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, ...
Apr 9, 2015
0
7